Burosumab therapy in children with X-linked hypophosphatemia

Thomas O. Carpenter, Michael P. Whyte, Erik Imel, Annemieke M. Boot, Wolfgang Högler, Agnès Linglart, Raja Padidela, William Van't Hoff, Meng Mao, Chao Yin Chen, Alison Skrinar, Emil Kakkis, Javier San Martin, Anthony A. Portale

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

BACKGROUND X-linked hypophosphatemia is characterized by increased secretion of fibroblast growth factor 23 (FGF-23), which leads to hypophosphatemia and consequently rickets, osteomalacia, and skeletal deformities. We investigated burosumab, a monoclonal antibody that targets FGF-23, in patients with X-linked hypophosphatemia. METHODS In an open-label, phase 2 trial, we randomly assigned 52 children with X-linked hypophosphatemia, in a 1:1 ratio, to receive subcutaneous burosumab either every 2 weeks or every 4 weeks; the dose was adjusted to achieve a serum phosphorus level at the low end of the normal range. The primary end point was the change from baseline to weeks 40 and 64 in the Thacher rickets severity total score (ranging from 0 to 10, with higher scores indicating greater disease severity). In addition, the Radiographic Global Impression of Change was used to evaluate rachitic changes from baseline to week 40 and to week 64. Additional end points were changes in pharmacodynamic markers, linear growth, physical ability, and patient-reported outcomes and the incidence of adverse events. RESULTS The mean Thacher rickets severity total score decreased from 1.9 at baseline to 0.8 at week 40 with every-2-week dosing and from 1.7 at baseline to 1.1 at week 40 with every-4-week dosing (P<0.001 for both comparisons); these improvements persisted at week 64. The mean serum phosphorus level increased after the first dose in both groups, and more than half the patients in both groups had levels within the normal range (3.2 to 6.1 mg per deciliter [1.0 to 2.0 mmol per liter]) by week 6. Stable serum phosphorus levels were maintained through week 64 with every-2-week dosing. Renal tubular phosphate reabsorption increased from baseline in both groups, with an overall mean increase of 0.98 mg per deciliter (0.32 mmol per liter). The mean dose of burosumab at week 40 was 0.98 mg per kilogram of body weight with every-2-week dosing and 1.50 mg per kilogram with every- 4-week dosing. Across both groups, the mean serum alkaline phosphatase level decreased from 459 U per liter at baseline to 369 U per liter at week 64. The mean standing-height z score increased in both groups, with greater improvement seen at all time points with every-2-week dosing (an increase from baseline of 0.19 at week 64) than with every-4-week dosing (an increase from baseline of 0.12 at week 64). Physical ability improved and pain decreased. Nearly all the adverse events were mild or moderate in severity. CONCLUSIONS In children with X-linked hypophosphatemia, treatment with burosumab improved renal tubular phosphate reabsorption, serum phosphorus levels, linear growth, and physical function and reduced pain and the severity of rickets.

Original languageEnglish (US)
Pages (from-to)1987-1998
Number of pages12
JournalNew England Journal of Medicine
Volume378
Issue number21
DOIs
StatePublished - May 24 2018

Fingerprint

Familial Hypophosphatemic Rickets
Rickets
Phosphorus
Serum
Reference Values
Phosphates
Hypophosphatemia
Kidney
Therapeutics
Pain
Osteomalacia
Aptitude
Growth
Alkaline Phosphatase
Monoclonal Antibodies
Body Weight
Incidence

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Carpenter, T. O., Whyte, M. P., Imel, E., Boot, A. M., Högler, W., Linglart, A., ... Portale, A. A. (2018). Burosumab therapy in children with X-linked hypophosphatemia. New England Journal of Medicine, 378(21), 1987-1998. https://doi.org/10.1056/NEJMoa1714641

Burosumab therapy in children with X-linked hypophosphatemia. / Carpenter, Thomas O.; Whyte, Michael P.; Imel, Erik; Boot, Annemieke M.; Högler, Wolfgang; Linglart, Agnès; Padidela, Raja; Van't Hoff, William; Mao, Meng; Chen, Chao Yin; Skrinar, Alison; Kakkis, Emil; Martin, Javier San; Portale, Anthony A.

In: New England Journal of Medicine, Vol. 378, No. 21, 24.05.2018, p. 1987-1998.

Research output: Contribution to journalArticle

Carpenter, TO, Whyte, MP, Imel, E, Boot, AM, Högler, W, Linglart, A, Padidela, R, Van't Hoff, W, Mao, M, Chen, CY, Skrinar, A, Kakkis, E, Martin, JS & Portale, AA 2018, 'Burosumab therapy in children with X-linked hypophosphatemia', New England Journal of Medicine, vol. 378, no. 21, pp. 1987-1998. https://doi.org/10.1056/NEJMoa1714641
Carpenter TO, Whyte MP, Imel E, Boot AM, Högler W, Linglart A et al. Burosumab therapy in children with X-linked hypophosphatemia. New England Journal of Medicine. 2018 May 24;378(21):1987-1998. https://doi.org/10.1056/NEJMoa1714641
Carpenter, Thomas O. ; Whyte, Michael P. ; Imel, Erik ; Boot, Annemieke M. ; Högler, Wolfgang ; Linglart, Agnès ; Padidela, Raja ; Van't Hoff, William ; Mao, Meng ; Chen, Chao Yin ; Skrinar, Alison ; Kakkis, Emil ; Martin, Javier San ; Portale, Anthony A. / Burosumab therapy in children with X-linked hypophosphatemia. In: New England Journal of Medicine. 2018 ; Vol. 378, No. 21. pp. 1987-1998.
@article{1bddb68900b943b79b341f9d6a33565e,
title = "Burosumab therapy in children with X-linked hypophosphatemia",
abstract = "BACKGROUND X-linked hypophosphatemia is characterized by increased secretion of fibroblast growth factor 23 (FGF-23), which leads to hypophosphatemia and consequently rickets, osteomalacia, and skeletal deformities. We investigated burosumab, a monoclonal antibody that targets FGF-23, in patients with X-linked hypophosphatemia. METHODS In an open-label, phase 2 trial, we randomly assigned 52 children with X-linked hypophosphatemia, in a 1:1 ratio, to receive subcutaneous burosumab either every 2 weeks or every 4 weeks; the dose was adjusted to achieve a serum phosphorus level at the low end of the normal range. The primary end point was the change from baseline to weeks 40 and 64 in the Thacher rickets severity total score (ranging from 0 to 10, with higher scores indicating greater disease severity). In addition, the Radiographic Global Impression of Change was used to evaluate rachitic changes from baseline to week 40 and to week 64. Additional end points were changes in pharmacodynamic markers, linear growth, physical ability, and patient-reported outcomes and the incidence of adverse events. RESULTS The mean Thacher rickets severity total score decreased from 1.9 at baseline to 0.8 at week 40 with every-2-week dosing and from 1.7 at baseline to 1.1 at week 40 with every-4-week dosing (P<0.001 for both comparisons); these improvements persisted at week 64. The mean serum phosphorus level increased after the first dose in both groups, and more than half the patients in both groups had levels within the normal range (3.2 to 6.1 mg per deciliter [1.0 to 2.0 mmol per liter]) by week 6. Stable serum phosphorus levels were maintained through week 64 with every-2-week dosing. Renal tubular phosphate reabsorption increased from baseline in both groups, with an overall mean increase of 0.98 mg per deciliter (0.32 mmol per liter). The mean dose of burosumab at week 40 was 0.98 mg per kilogram of body weight with every-2-week dosing and 1.50 mg per kilogram with every- 4-week dosing. Across both groups, the mean serum alkaline phosphatase level decreased from 459 U per liter at baseline to 369 U per liter at week 64. The mean standing-height z score increased in both groups, with greater improvement seen at all time points with every-2-week dosing (an increase from baseline of 0.19 at week 64) than with every-4-week dosing (an increase from baseline of 0.12 at week 64). Physical ability improved and pain decreased. Nearly all the adverse events were mild or moderate in severity. CONCLUSIONS In children with X-linked hypophosphatemia, treatment with burosumab improved renal tubular phosphate reabsorption, serum phosphorus levels, linear growth, and physical function and reduced pain and the severity of rickets.",
author = "Carpenter, {Thomas O.} and Whyte, {Michael P.} and Erik Imel and Boot, {Annemieke M.} and Wolfgang H{\"o}gler and Agn{\`e}s Linglart and Raja Padidela and {Van't Hoff}, William and Meng Mao and Chen, {Chao Yin} and Alison Skrinar and Emil Kakkis and Martin, {Javier San} and Portale, {Anthony A.}",
year = "2018",
month = "5",
day = "24",
doi = "10.1056/NEJMoa1714641",
language = "English (US)",
volume = "378",
pages = "1987--1998",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "21",

}

TY - JOUR

T1 - Burosumab therapy in children with X-linked hypophosphatemia

AU - Carpenter, Thomas O.

AU - Whyte, Michael P.

AU - Imel, Erik

AU - Boot, Annemieke M.

AU - Högler, Wolfgang

AU - Linglart, Agnès

AU - Padidela, Raja

AU - Van't Hoff, William

AU - Mao, Meng

AU - Chen, Chao Yin

AU - Skrinar, Alison

AU - Kakkis, Emil

AU - Martin, Javier San

AU - Portale, Anthony A.

PY - 2018/5/24

Y1 - 2018/5/24

N2 - BACKGROUND X-linked hypophosphatemia is characterized by increased secretion of fibroblast growth factor 23 (FGF-23), which leads to hypophosphatemia and consequently rickets, osteomalacia, and skeletal deformities. We investigated burosumab, a monoclonal antibody that targets FGF-23, in patients with X-linked hypophosphatemia. METHODS In an open-label, phase 2 trial, we randomly assigned 52 children with X-linked hypophosphatemia, in a 1:1 ratio, to receive subcutaneous burosumab either every 2 weeks or every 4 weeks; the dose was adjusted to achieve a serum phosphorus level at the low end of the normal range. The primary end point was the change from baseline to weeks 40 and 64 in the Thacher rickets severity total score (ranging from 0 to 10, with higher scores indicating greater disease severity). In addition, the Radiographic Global Impression of Change was used to evaluate rachitic changes from baseline to week 40 and to week 64. Additional end points were changes in pharmacodynamic markers, linear growth, physical ability, and patient-reported outcomes and the incidence of adverse events. RESULTS The mean Thacher rickets severity total score decreased from 1.9 at baseline to 0.8 at week 40 with every-2-week dosing and from 1.7 at baseline to 1.1 at week 40 with every-4-week dosing (P<0.001 for both comparisons); these improvements persisted at week 64. The mean serum phosphorus level increased after the first dose in both groups, and more than half the patients in both groups had levels within the normal range (3.2 to 6.1 mg per deciliter [1.0 to 2.0 mmol per liter]) by week 6. Stable serum phosphorus levels were maintained through week 64 with every-2-week dosing. Renal tubular phosphate reabsorption increased from baseline in both groups, with an overall mean increase of 0.98 mg per deciliter (0.32 mmol per liter). The mean dose of burosumab at week 40 was 0.98 mg per kilogram of body weight with every-2-week dosing and 1.50 mg per kilogram with every- 4-week dosing. Across both groups, the mean serum alkaline phosphatase level decreased from 459 U per liter at baseline to 369 U per liter at week 64. The mean standing-height z score increased in both groups, with greater improvement seen at all time points with every-2-week dosing (an increase from baseline of 0.19 at week 64) than with every-4-week dosing (an increase from baseline of 0.12 at week 64). Physical ability improved and pain decreased. Nearly all the adverse events were mild or moderate in severity. CONCLUSIONS In children with X-linked hypophosphatemia, treatment with burosumab improved renal tubular phosphate reabsorption, serum phosphorus levels, linear growth, and physical function and reduced pain and the severity of rickets.

AB - BACKGROUND X-linked hypophosphatemia is characterized by increased secretion of fibroblast growth factor 23 (FGF-23), which leads to hypophosphatemia and consequently rickets, osteomalacia, and skeletal deformities. We investigated burosumab, a monoclonal antibody that targets FGF-23, in patients with X-linked hypophosphatemia. METHODS In an open-label, phase 2 trial, we randomly assigned 52 children with X-linked hypophosphatemia, in a 1:1 ratio, to receive subcutaneous burosumab either every 2 weeks or every 4 weeks; the dose was adjusted to achieve a serum phosphorus level at the low end of the normal range. The primary end point was the change from baseline to weeks 40 and 64 in the Thacher rickets severity total score (ranging from 0 to 10, with higher scores indicating greater disease severity). In addition, the Radiographic Global Impression of Change was used to evaluate rachitic changes from baseline to week 40 and to week 64. Additional end points were changes in pharmacodynamic markers, linear growth, physical ability, and patient-reported outcomes and the incidence of adverse events. RESULTS The mean Thacher rickets severity total score decreased from 1.9 at baseline to 0.8 at week 40 with every-2-week dosing and from 1.7 at baseline to 1.1 at week 40 with every-4-week dosing (P<0.001 for both comparisons); these improvements persisted at week 64. The mean serum phosphorus level increased after the first dose in both groups, and more than half the patients in both groups had levels within the normal range (3.2 to 6.1 mg per deciliter [1.0 to 2.0 mmol per liter]) by week 6. Stable serum phosphorus levels were maintained through week 64 with every-2-week dosing. Renal tubular phosphate reabsorption increased from baseline in both groups, with an overall mean increase of 0.98 mg per deciliter (0.32 mmol per liter). The mean dose of burosumab at week 40 was 0.98 mg per kilogram of body weight with every-2-week dosing and 1.50 mg per kilogram with every- 4-week dosing. Across both groups, the mean serum alkaline phosphatase level decreased from 459 U per liter at baseline to 369 U per liter at week 64. The mean standing-height z score increased in both groups, with greater improvement seen at all time points with every-2-week dosing (an increase from baseline of 0.19 at week 64) than with every-4-week dosing (an increase from baseline of 0.12 at week 64). Physical ability improved and pain decreased. Nearly all the adverse events were mild or moderate in severity. CONCLUSIONS In children with X-linked hypophosphatemia, treatment with burosumab improved renal tubular phosphate reabsorption, serum phosphorus levels, linear growth, and physical function and reduced pain and the severity of rickets.

UR - http://www.scopus.com/inward/record.url?scp=85047731982&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047731982&partnerID=8YFLogxK

U2 - 10.1056/NEJMoa1714641

DO - 10.1056/NEJMoa1714641

M3 - Article

C2 - 29791829

AN - SCOPUS:85047731982

VL - 378

SP - 1987

EP - 1998

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 21

ER -